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http://dxObjective: Patients referred for implantable continuous-flow left ventricular assist devices (cfLVAD) frequently
have preoperative right heart failure and tricuspid regurgitation (TR). The objective of this report is to examine
early clinical benefits of concomitant tricuspid surgery for these patients.
Methods: Sixty-one of 200 consecutive cfLVAD patients at our institution displayed preimplant right heart
dysfunction and significant TR. Thirty-three underwent cfLVAD plus a tricuspid valve procedure (TVP), and
28 had cfLVAD alone. Preimplant characteristics and clinical outcomes were retrospectively studied. As previ-
ously described, post-LVAD right ventricular failure was defined as need for right ventricular assist device
(RVAD) support or greater than 14 days of intravenous inotropic support.
Results: Preimplant characteristics were similar between the 2 groups. Cardiopulmonary bypass time was
increased for the group that received concomitant TVPs. The most common TVP consisted of an undersizing
ring annuloplasty. The cfLVAD-alone group had greater TR after implant relative to the cfLVADþTVP group.
The cfLVAD-alone group experienced greater postprocedure right ventricular failure relative to cfLVADþTVP
(46.4% vs 18.2%; P<.05). Furthermore, prolonged hospitalization was increased for the cfLVAD-alone group
versus the cfLVADþTVP. Survival was similar between the 2 groups.
Conclusions: Concomitant TVP appears to reduce postprocedure right ventricular failure for patients with sig-
nificant TR undergoing cfLVAD implantation. (J Thorac Cardiovasc Surg 2012;144:1217-21)T
XPatients referred for support with an implantable left
ventricular assist device (LVAD) frequently have right ven-
tricular (RV) failure in addition to left heart failure. Some
of these patients continue to manifest RV failure after
LVAD implantation, which results in the need for RV assist
device (RVAD) support or prolonged intravenous inotropic
agent support. The advent of continuous-flow designs for
LVAD pumps has resulted in reduced post-LVADRV failure,
but this complication continues to affect more than 20% of
patients in recent LVAD trials.1 Furthermore, the presence
of post-LVAD RV failure, even in patients with continuous-
flowLVADs (cfLVADs), is associatedwith reduced survival.2
This complicationmay also affect duration of hospitalization,
quality of life, and functional status for cfLVAD recipients.
Most patients with RV failure who undergo implantable
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The Journal of Thoracic and Carregurgitation (TR).3 Usually this TR is functional and
reflects RV pressure or volume overload. The benefits of
a concomitant tricuspid valve procedure (TVP) to correct
TR at the time of LVAD implantation have not been
rigorously examined. We previously reviewed the impact
of concomitant tricuspid valve surgery in a cohort of
patients that included many who received first-generation
pulsatile LVADs.4 In this study, the role of concomitant
tricuspid valve surgery is examined in a more modern expe-
rience consisting solely of patients having a cfLVAD.
In this study, a consecutive group of patients undergoing
cfLVAD implantation with RV failure and significant TR
are examined. The benefits of the concomitant TVP are
studied as some of the patients received a concomitant
TVP and others did not. This study focuses specifically on
whether concomitant TVP is associated with reduced RV
failure after the LVAD implantation. These results should
provide insight for the clinical judgment of when concom-
itant tricuspid surgery should be attempted. Furthermore, it
examines whether concomitant tricuspid surgery may be
a strategy to avoid the need for mechanical RV support.METHODS
Permission for this study was granted by the Institutional Review Board
of Duke University Medical Center, and need for patient consent was
waived. From 2005 to 2011, 200 consecutive cfLVADs were implanted
at a single institution (Duke). Of the 200 patients, 61 had significant
preimplant TR on preoperative echocardiography; these patientsdiovascular Surgery c Volume 144, Number 5 1217
Abbreviations and Acronyms
cfLVAD ¼ continuous-flow left ventricular assist
device
CPB ¼ cardiopulmonary bypass
LVAD ¼ left ventricular assist device
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
TR ¼ tricuspid regurgitation
TVP ¼ tricuspid valve procedure
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Xcomprised the study group for this report. All transthoracic and transeso-
phageal echocardiograms that were performed during the week before
the LVAD implant were reviewed. Patients who met the American Society
of Echocardiography’s guidelines for moderate or severe TR defined the
‘‘significant TR’’ group. Patients with prior TVPs and those undergoing
redo LVAD implants were excluded. Preimplant characteristics and
hemodynamics were acquired for all 61 patients who met the definition
for significant TR.
Of the 61 patients, 33 underwent concomitant TVPs (cfLVADþTVP),
while 28 underwent LVAD alone (cfLVAD-alone). None of the patients
underwent plannedRVAD support, and all wereweaned from cardiopulmo-
nary bypass (CPB). Use of RVAD support was based on clinical evidence of
RV failure, including inability to fill the LVAD, inadequate systemic output
(cardiac index or LVAD flow index<2.0 L/min/m2), and elevated central
venous pressure (>20 mmHg) despite multiple inotropes after weaning off
CPB. All patients received inhaled nitric oxide at the time of weaning from
CPB. During the postoperative recovery, inhaled nitric oxide was transi-
tioned to inhaled prostaglandin or oral sildenafil, based on postoperative
hemodynamics and clinical status.
Use of postoperative intravenous inotropes was based on hemodynam-
ics, end organ function (ie, blood urea nitrogen, creatinine), and signs of
right heart failure (weight gain, ascites, peripheral edema).
Postoperative outcomes were retrospectively extracted from the
medical record. Postimplant RV failure was defined as need for RVAD or
prolonged inotropes for greater than 14 days. Postoperative serum
creatinine was recorded as a gauge of renal function. Postoperative length
of intensive care unit stay and length of hospitalization were recorded and
compared for the 2 groups. Echocardiograms with assessment of TR sever-
ity were performed on all patients during the implant hospitalization,
before and after the procedure; TR grades were assigned according to
the American Society of Echocardiography’s guidelines. In addition, pre-
operative maximal tricuspid annular diameters were measured by transeso-
phageal echocardiography in the midesophageal 4-chamber view and in the
RV inflow/outflow view and compared between the 2 groups.
Preimplant characteristics that were normally distributed are expressed
as mean values with standard deviations and are compared with an unpaired
Student t test. Durations of postimplant inotropic support and hospitaliza-
tion are reported as median days with the 25th and 75th percentiles and are
compared with a Mann-Whitney test. Postoperative renal dysfunction is
defined as a 50% increase in the serum creatinine relative to the immediate
preimplant value; both postoperative renal dysfunction and RVAD use are
presented as percentages and compared with the Fischer exact test.
RESULTS
Table 1 details the preoperative characteristics of the
2 groups. Patients within each group had similar ages and
pulmonary artery catheter–based hemodynamics. Both
groups had a small incidence of other procedures such as
closure of a patent foramen ovale. The 2 groups consisted1218 The Journal of Thoracic and Cardiovascular Surof patients who underwent implantation during the same
era, with similar surgeons, intensive care unit staffing, and
treatment protocols. Tricuspid annular dimensions were
similar between the cfLVAD-alone group and the group
that received the concomitant TVPs. The total CPB time
was increased for the group receiving the concomitant
TVPs by approximately 1 hour.
Table 2 shows the type of TVPs for the cfLVAD and TVP
groups. A minority of patients required replacement with
a bioprosthesis; there were no mechanical replacements.
The most common procedure consisted of an undersizing
annuloplasty ring repair. We have recently begun using
semirigid rings for tricuspid annuloplasty.
Figure 1 depicts echocardiographic TR grade before
and after LVAD implantation in the cfLVAD-alone and
cfLVADþTVP groups. Almost 50% of the patients in the
cfLVAD-alone group continued to demonstrate significant
(moderate or severe) TR after LVAD implantation. This is
similar to our earlier study on TR in LVAD patients receiv-
ing pulsatile devices.4 The majority of patients in the
cfLVADþTVP group had insignificant TR (less than moder-
ate) at follow-up echocardiogram.
Table 3 describes post-LVAD outcomes between the
2 groups. Patients in the cfLVAD-alone group were
more likely to experience postoperative RV failure
(P< .05) and also more likely to require a postoperative
RVAD (P < .05). Postimplant inotropic agent use also
tended to be greater in the cfLVAD-alone group versus the
cfLVADþTVP group (12.1 vs 9.72 days; P ¼ .16). Postim-
plant acute kidney injury tended to be less in the
cfLVADþTVP group versus the cfLVAD-alone group.
Also, the cfLVAD-alone group had statistically more pa-
tients requiring prolonged hospitalization (>30 days;
P< .05) when compared with the cfLVADþTVP group.
Mortality rates were similar for the 2 groups.
RV failure is composed of the fraction of patients
requiring postoperative RVADs or prolonged intravenous
inotropic support. Figure 2 illustrates the incidence of RV
failure in both groups after LVAD implantation. Forty-six
percent of patients in the cfLVAD-alone group exhibited
post-LVAD RV failure versus only 18% of the
cfLVADþTVP group; most of the difference resulted from
greater RVAD requirement for the cfLVAD-alone group.
The overall incidence of RV failure for the cfLVAD-alone
group is greater than that of previous series, which is consis-
tent with the fact that these patients represent a high risk
group for RV failure.2 This statement is supported by data
from Table 1, which showed reduced RV systolic volume
index and increased ratio of central venous pressure to pul-
monary capillary wedge pressure for both groups.
DISCUSSION
Recent studies have suggested that use of cfLVADs
versus older pulsatile LVADs is associated with a reducedgery c November 2012
TABLE 1. Pre-cfLVAD patient characteristics
cfLVAD-alone
(n ¼ 28)
cfLVADþTVP
(n ¼ 33)
P
value
Age (y) 59 56 .15
Sex (% male) 54 66 .45
Heart failure etiology (% NICM) 64 44 .12
BUN 32 40 .08
Creatinine (mg/dL) 1.7 1.6 .46
Heart rate (beats/min) 93 88 .27
CVP (mm Hg) 18 19 .16
Mean PAP (mm Hg) 38 38 .27
PCWP (mm Hg) 27 26 .44
Pulmonary vascular resistance
(Wood inits)
3.6 3.4 .30
CVP/PCWP 0.651 0.739 .10
Cardiac index (L/min/m2) 1.8 1.78 .45
RVSWI (mL/min/m2) 410 446 .32
Mixed venous oxygen
saturation (%)
46 46 .37
Preoperative ventilator (%) 14 13 1.0
Year of most implantations 2008 2010
Era of implantations 2005-2011 2005-2011
CPB times (min) 111 179 <.001
Nontricuspid concomitant
procedures (%)
19 18 .4
Preimplant TV annular diameter
(4-chamber view) (cm)
4.35 4.38 NS
Preimplant TV annular diameter
(RV inflow and outflow view)
(cm)
4.66 4.58 NS
cfLVAD-alone, Continuous-flow left ventricular assist device alone; cfLVADþTVP,
continuous-flow left ventricular assist device plus tricuspid valve procedure;
NICM, nonischemic cardiomyopathy; BUN, blood urea nitrogen;CVP, central venous
pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pres-
sure; RVSWI, Right Ventricular Stroke Work Index; CPB, cardiopulmonary bypass;
TV, tricuspid valve; RV, right ventricular; NS, not significant.
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Xincidence of RV failure.1 Nevertheless, even in an era of
cfLVADs, RV failure remains an important postimplant
complication that affects 20% of patients and negatively af-
fects survival outcomes.1,2 While preimplant risk factors for
this complication have been described, effective treatment
or preventive measures are not well understood.1,2 We3 pre-
viously reported that TR is commonly encountered before
LVAD implantation, does not resolve with mechanical left
ventricular unloading, and is associated with postimplant
RV failure. In this report, in a cohort of patients withTABLE 2. Type of tricuspid valve procedures
Procedure No.
Bioprosthetic replacement 4
Undersizing ring annuloplasty repair 29
Flexible ring 22
Semirigid ring 7
Total 33
The Journal of Thoracic and Carsignificant TR who received cfLVADs, we examine the
benefits of concomitant TVPs to reduce postimplant RV
failure.
Recently, Maltais and associates5 reported the echocar-
diographic changes associated with cfLVAD support and
concomitant tricuspid valve annuloplasty. Repeat echocar-
diography at 1 month after implant demonstrated that the
group that received concomitant TVP displayed reduced
TR and decreased RV volume. The current report
compliments this echocardiographic study by examining
the clinical outcomes that define RV failure for a cohort
of cfLVAD patients with significant TR who undergo either
concomitant tricuspid valve surgery or LVAD implantation
alone. Importantly, postimplant RV failure, defined by need
for RVAD support or prolonged intravenous inotropic
infusion (>14 days), is reduced in the group undergoing
concomitant TVPs. This study suggests that concomitant
tricuspid surgery may be a simple intraoperative strategy
to help avoid RV failure.
Our earlier study of TVP during pulsatile or nonpulsatile
LVAD implantation suggested a survival benefit for
concomitant TVP, and a recent study from Atrache and col-
leagues6 also suggests a survival benefit of concomitant
TVP and LVAD implantation.4 The current report and that
of Maltais and coworkers5 do not demonstrate a survival
benefit associated with concomitant TVPs. Several possible
explanations can be offered for the equivalent survival out-
comes found in this report and that of Maltais’ group.5 First,
this report examines a relatively small number of subjects
and may be inadequately powered to show survival differ-
ences. Furthermore, this study does not randomize patients
to receive concomitant TVPs, and the group that received
the TVPs may have had worse RV performance before the
LVAD implantation relative to those who were delegated
to not undergo the concomitant procedure. For example,
the group that underwent the concomitant TVPs shows
a trend to have higher preoperative central venous pres-
sure/pulmonary capillary wedge pressure ratios. The fact
that patients were not randomized to either receive or not
receive TVP is the single most important limitation to all
conclusions. Also, a small fraction of the LVAD-alone
group experienced improvement in their postimplant TR
(even though they did not receive a procedure), which
may have positively affected survival. Another explanation
for the equivalent survival for the 2 groups is that the group
undergoing LVAD alone may have received a variety of
additional postimplant treatments for RV failure (eg, pul-
monary vasodilators) that allowed for better hemodynamics
and survival.
Although this study supports the use of concomitant
TVPs for LVAD patients with significant TR, several
important questions remain. First, the group undergoing
concomitant TVPs included both moderate and severe
preimplant grades of TR. It is unclear what preoperativediovascular Surgery c Volume 144, Number 5 1219
FIGURE 1. Preoperative echocardiographic tricuspid regurgitation (TR) grade versus follow-up TR grade in cfLVAD-alone versus cfLVADþTVP groups.
cfLVAD-alone, Continuous-flow left ventricular assist device alone; cfLVADþTVP, continuous-flow left ventricular assist device plus tricuspid valve proce-
dure; LVAD, left ventricular assist device.
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Dreyfus and colleagues7 suggest that the decision for annu-
loplasty in the setting of functional TR should be based on
annular size (dilation) rather than severity of regurgitation.
This line of thought suggests that the surgical annuloplasty
may have a positive impact on RV reverse remodeling inde-
pendent of reducing the volume loading associated with TR.
Therefore, it is unclear whether tricuspid annuloplasty
should be deployed for annular dilation alone. AnotherTABLE 3. Clinical outcome measures post-cfLVAD implantation
cfLVAD-alone cfLVADþTVP P value
RV failure 13/28 (46.4%) 6/33 (18.2%) <.05
Patients requiring>30
days after LVAD
hospitalization
12/28 (42.9%) 6/33 (18.2%) <.05
Post-cfLVAD acute
kidney injury
10/28 (32.14%) 7/33 (15.15%) .21
Duration of
hospitalization (d)
(average, median,
25th, and 75th
percentiles)
32 (20; 15, 37) 24 (19; 13, 27) .21
Need for
rehospitalization in
first year
17/19 (89.47%) 22/26 (84.6%) 1.0
Thirty-day mortality 1/28 (3.5%) 1/32 (3.13%) 1.0
One-year mortality 5/22 (22.73%) 3/24 (12.5%) .45
cfLVAD-alone, Continuous-flow left ventricular assist device alone; cfLVADþTVP,
continuous-flow left ventricular assist device plus tricuspid valve procedure;
1220 The Journal of Thoracic and Cardiovascular Surimportant question relates to the deployment of RVAD sup-
port in patients who undergo cfLVAD implantation. This
study suggests that many patients who may be considered
for RVAD support may benefit from tricuspid annuloplasty
and that this strategy should be attempted first before
committing the patient to biventricular support, whichFIGURE 2. Postoperative right ventricular (RV) failure for cfLVAD-alone
versus cfLVADþTVP. Bars represent the incidence of need for a right ven-
tricular assist device (gray) or prolonged inotrope use (>14 days; black) for
each group. *P<.05. cfLVAD-alone, Continuous-flow left ventricular as-
sist device alone; cfLVADþTVP, continuous-flow left ventricular assist de-
vice plus tricuspid valve procedure.
gery c November 2012
Piacentino et al Cardiothoracic Transplantationadds to the complexity and cost of the mechanical circula-
tory support. In addition, tricuspid annuloplasty may be
complementary to temporary RVAD support and may facil-
itate later weaning from the RVAD.
CONCLUSIONS
This study examines a modern cohort of patients under-
going implantation of a cfLVAD who displayed preopera-
tive RV failure and significant TR. Roughly half of the
group underwent LVAD alone, whereas the other half had
concomitant TVPs. The group that underwent concomitant
TVP required more prolonged CPB times but, despite this,
experienced reduced postimplant RV failure as described by
less need for RVAD support and reduced inotropic infusion
support. Furthermore, prolonged hospitalizations were less
frequent for the group that underwent concomitant TVP.
Therefore, patients undergoing implantable cfLVADs who
have moderate or severe TR should be considered for
concomitant TVP to reduce postimplant RV dysfunction.The Journal of Thoracic and CarReferences
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